(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
Dominating the Remote Work Way of life: Individual Systems- Israel's Druze use AI to present to UN testimonies of 'sexual terrorism' against Syrian Druze women
- Finding Your Motivation: Moves toward a Satisfying Life
- Some super-smart dogs can pick up new words just by eavesdropping
- How color-changing, bacteria-infused spacesuits could help keep future astronauts safe from space radiation
- From School Dropout to Example of overcoming adversity: My Excursion
- Grasping the Commencement of Criminal Cases: An Extensive Outline
- Don't miss Jupiter shining close to the waning gibbous moon on Dec. 7
- Dental Embed Innovation: An Achievement in Helpful Dentistry
